Abbott’s next-generation Amulet LAA occlusion device earns CE Mark
August 27, 2026
Abbott’s (NYSE: ABT) Amulet 360 left atrial appendage (LAA) occlusion device received CE mark, the company announced today.
Abbott’s (NYSE: ABT) Amulet 360 left atrial appendage (LAA) occlusion device received CE mark, the company announced today.
A new study from the University of Oulu suggests that gut bacteria may send different biological signals in Parkinson’s disease. The findings add to growing evidence that changes in the gut could be linked to Parkinson’s disease and may eventually help researchers identify new underlying mechanisms for the condition.
A new preclinical study has demonstrated that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models. This combination therapy induces irreparable DNA damage in cancer cells while also stimulating the body’s immune system to combat the disease. The research is published in the journal Cell Reports Medicine.
Console-free, single-use cryoprobe brings cryobiopsy to the bronchoscopy suite without dedicated capital equipment
With more than 7 million Americans living with Alzheimer’s dementia—a number projected to reach nearly 13 million by 2050—new Emory University research suggests that higher vitamin D supplement intake may be associated with better cognitive function in adults at elevated risk of dementia.
Doctor-created Livi addresses a long-overlooked need in post-sex intimate health, available exclusively at MyLivi.com.
Filing targets TPN, propofol and other IV therapies where undetected infiltration
and extravasation can cause severe injury
HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition’s established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.
Wandercraft, a Paris-based robotics company, announced that the FDA has granted clearance for Eve, its personal self-balancing exoskeleton designed to support upright mobility.
BEIJING, Aug. 11, 2026 /PRNewswire/ — Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) (“Datasea” or the “Company”), a technology company focused on acoustic high-tech and AI multimodal digital solutions, today announced that Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd. (“Shuhai Jingwei”), the Company’s variable interest entity in China, has completed establishment registration and device listing with the U.S. Food and Drug Administration (“FDA”) for its NeuroVibe Biofeedback System, including products NV-02 and NV-03.